Drug Discovery and Development: Present and FutureIzet Kapetanović BoD – Books on Demand, 16 déc. 2011 - 542 pages Drug discovery and development process aims to make available medications that are safe and effective in improving the length and quality of life and relieving pain and suffering. However, the process is very complex, time consuming, resource intensive, requiring multi-disciplinary expertise and innovative approaches. There is a growing urgency to identify and develop more effective, efficient, and expedient ways to bring safe and effective products to the market. The drug discovery and development process relies on the utilization of relevant and robust tools, methods, models, and validated biomarkers that are predictive of clinical effects in terms of diagnosis, prevention, therapy, and prognosis. There is a growing emphasis on translational research, a bidirectional bench to the bedside approach, in an effort to improve the process efficiency and the need for further innovations. The authors in the book discuss the current and evolving state of drug discovery and development. |
Table des matières
Evolutionary Biology and Drug Development | 25 |
Novel Oncology Drug Development | 43 |
Drug Discovery into the 21st Century | 69 |
Genetically Engineered Mouse Models | 99 |
Genetic Pharmacotherapy | 125 |
Critical Human HepatocyteBased In Vitro | 151 |
The Use of In Vitro 3D Cell Models | 169 |
Towards Understanding Drugs | 231 |
Assessment of Cell Cycle Inhibitors | 323 |
ImageBased HighContent | 339 |
Recent Advances in Biotherapeutics | 363 |
Drug Discovery by Aptamers | 379 |
Streamlining ICH | 391 |
Current | 427 |
Silver Nanoparticles Universal Multifunctional | 463 |
Mesenchymal Stem Cells | 472 |
Expressions et termes fréquents
acid activity agents analysis antibody applications approach aptamers assays Ayurveda binding Biol biological biomarkers Biomolecular Chemistry Vol biotherapeutics BRAF brain breast cancer cancer cells cell lines cellular cetuximab chemical biology Clin clinical trials compounds dendrimers disease dose doxorubicin drug delivery drug development drug discovery effects efficacy EGFR enzyme erlotinib evaluation expression fluorescence function gefitinib gene genetic pharmacotherapy genome growth factor hepatocytes HER2 human hepatocytes identified imaging increased induced inhibition inhibitors interactions ISSN Journal kinase ligands liposomes lung mechanism medicine melanoma metabolism metastatic methods mice models molecular mouse MSCs mutations nanoparticles novel Nrf2 oncogenic Organic & Biomolecular paclitaxel pathway patients peptide pharmaceutical phase polymorphs potential preclinical predictive protein receptor recombinant reported resistance response screening selection silver nanoparticles small molecules specific strategies structure studies synthesis testing therapeutic therapy throughput tissue toxicity transgenic trastuzumab treatment tumor vitro vivo